Related Experiment Video

Updated: Mar 17, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
11:30

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

2.6K

[Hypocalcemia Induced by Denosumab in Patients with Renal Insufficiency]

Kota Ishida1, Risa Shimizu, Iwao Endo

  • 1Dept. of Pharmacy, Japanese Red Cross MedicalCenter.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 20, 2016
PubMed

Insights

Continuous denosumab administration in patients with impaired renal function, specifically those with creatinine clearance below 40 mL/min, can lead to decreased serum calcium levels. Close monitoring of calcium is recommended for these patients.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Denosumab, a monoclonal antibody, is administered subcutaneously.
  • Dosage adjustments for denosumab are not typically recommended for impaired renal function.
  • Hypocalcemia has been reported in patients with renal impairment receiving denosumab, necessitating cautious administration.

Purpose of the Study:

  • To investigate the impact of denosumab on serum calcium concentrations in patients with renal impairment.
  • To assess the incidence of hypocalcemia following continuous denosumab administration in this population.

Main Methods:

  • Retrospective investigation of serum calcium levels.
  • Analysis of patients with creatinine clearance (Ccr) < 40 mL/min receiving continuous denosumab.
  • Monitoring of serum calcium concentrations post-administration.

Main Results:

  • Continuous denosumab administration led to decreased serum calcium levels in patients with Ccr < 40 mL/min.
  • Grade 2 or higher hypocalcemia was observed in 75% of the studied patients.
  • Significant reduction in serum calcium was noted during continuous treatment.

Conclusions:

  • Denosumab administration in patients with renal impairment requires careful consideration.
  • Close monitoring of serum calcium concentrations is crucial for patients with renal impairment receiving continuous denosumab.
  • Potential for clinically significant hypocalcemia exists in this patient group.

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.8K

Related Concept Videos

Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
6.7K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.2K
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
6.0K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
890
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
566
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.9K